Effects of Ivabradine and Ranolazine in Patients With Microvascular Angina Pectoris

Angelo Villano, Antonino Di Franco, Roberto Nerla, Alfonso Sestito, Pierpaolo Tarzia, Priscilla Lamendola, Antonio Di Monaco, Filippo Maria Sarullo, Gaetano Antonio Lanza, Filippo Crea

Risultato della ricerca: Contributo in rivistaArticolo in rivista

98 Citazioni (Scopus)


Patients with microvascular angina (MVA) often have persistence of symptoms despite full classical anti-ischemic therapy. In this study, we assessed the effect of ivabradine and ranolazine in MVA patients. We randomized 46 patients with stable MVA (effort angina, positive exercise stress test [EST], normal coronary angiography, coronary flow reserve <2.5), who had symptoms inadequately controlled by standard anti-ischemic therapy, to ivabradine (5 mg twice daily), ranolazine (375 mg twice daily), or placebo for 4 weeks. The Seattle Angina Questionnaire (SAQ), EuroQoL scale, and EST were assessed at baseline and after treatment. Coronary microvascular dilation in response to adenosine and to cold pressor test and peripheral endothelial function (by flow-mediated dilation) were also assessed. Both drugs improved SAQ items and EuroQoL scale compared with placebo (p <0.01 for all), with ranolazine showing some more significant effects compared with ivabradine, on some SAQ items and EuroQoL scale (p <0.05). Time to 1-mm ST-segment depression and EST duration were improved by ranolazine compared with placebo. No effects on coronary microvascular function and on flow-mediated dilation were observed with drugs or placebo. In conclusion, ranolazine and ivabradine may have a therapeutic role in MVA patients with inadequate control of symptoms in combination with usual anti-ischemic therapy.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
Stato di pubblicazionePubblicato - 2013


  • ivabradine
  • microvascular angina
  • ranolazine


Entra nei temi di ricerca di 'Effects of Ivabradine and Ranolazine in Patients With Microvascular Angina Pectoris'. Insieme formano una fingerprint unica.

Cita questo